Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
496. |
ECCT/10/11/06 | Randomized Comparison of ART Alone versus ART with Immediate Chemotherapy A5264/AMC 067 "A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Li1mited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)" |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Walter Reed Project Kericho (Kericho county) 2. Moi University Clinical Research Centre (Uasin Gishu county) |
View |
497. |
ECCT/13/07/03 | Pharmacokinetic and pharmacodynamic studies of efficacy, tolerability and safety of higher dosage rifapentine for treatment of tuberculosis |
Principal Investigator(s) 1. Dr Lena Matata Site(s) in Kenya KEMRI-CDC |
View |
498. |
ECCT/13/08/01 | M72/AS01 E A phase IIb, double-blind, randomised, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of GSK Biologicals’ candidatetuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults aged 18-50 years, living in a TB endemic region. |
Principal Investigator(s) 1. Dr Videlis Nduba Site(s) in Kenya KEMRI-CDC |
View |
499. |
ECCT/12/07/01 | MULTI-OCTAVE (Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure) A5288 "Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure" (MULTI-OCTAVE) |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya Moi University Clinical Research Centre |
View |
500. |
ECCT/09/03/01 | REMoxTB A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol, isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis |
Principal Investigator(s) 1. Evans Inyangala Amukoye Site(s) in Kenya Kibera D.O Health Centre |
View |